Johnson & Johnson (JNJ) Rating Increased to Buy at Vetr Inc.
Johnson & Johnson (NYSE:JNJ) was upgraded by Vetr from a “hold” rating to a “buy” rating in a research note issued on Tuesday. The brokerage presently has a $121.49 price objective on the stock. Vetr‘s price target would indicate a potential upside of 5.27% from the company’s current price.
JNJ has been the topic of several other research reports. Credit Suisse Group AG reissued a “neutral” rating and set a $123.00 price target on shares of Johnson & Johnson in a research note on Monday, September 19th. Wells Fargo & Co. reissued a “buy” rating on shares of Johnson & Johnson in a research note on Monday, July 11th. BMO Capital Markets reissued an “outperform” rating and set a $132.00 price target on shares of Johnson & Johnson in a research note on Wednesday, July 20th. Zacks Investment Research upgraded Johnson & Johnson from a “hold” rating to a “buy” rating and set a $139.00 price objective for the company in a research report on Friday, August 5th. Finally, Jefferies Group lifted their price objective on Johnson & Johnson from $113.00 to $119.00 and gave the stock a “hold” rating in a research report on Thursday, August 4th. Two research analysts have rated the stock with a sell rating, eleven have issued a hold rating and ten have assigned a buy rating to the company’s stock. The company has an average rating of “Hold” and an average price target of $120.12.
Johnson & Johnson (NYSE:JNJ) traded down 2.60% on Tuesday, hitting $115.41. The stock had a trading volume of 12,598,255 shares. Johnson & Johnson has a one year low of $94.28 and a one year high of $126.07. The company’s 50-day moving average price is $118.58 and its 200 day moving average price is $117.61. The firm has a market cap of $315.75 billion, a price-to-earnings ratio of 21.51 and a beta of 0.62.
This story is the sole property of American Banking News and it was originally published by American Banking News. If you are reading this story on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. The original version of this article is available at http://www.americanbankingnews.com/2016/10/18/johnson-johnson-jnj-rating-increased-to-buy-at-vetr-inc.html
Johnson & Johnson (NYSE:JNJ) last announced its quarterly earnings results on Tuesday, October 18th. The company reported $1.68 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $1.65 by $0.03. The business had revenue of $17.80 billion for the quarter, compared to analyst estimates of $17.71 billion. Johnson & Johnson had a return on equity of 24.70% and a net margin of 20.97%. The company’s quarterly revenue was up 4.2% on a year-over-year basis. During the same quarter in the previous year, the company earned $1.49 EPS. Analysts expect that Johnson & Johnson will post $6.69 earnings per share for the current year.
In other news, VP Dominic J. Caruso sold 41,146 shares of Johnson & Johnson stock in a transaction on Tuesday, July 26th. The stock was sold at an average price of $125.01, for a total transaction of $5,143,661.46. Following the sale, the vice president now directly owns 157,819 shares in the company, valued at approximately $19,728,953.19. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, CAO Ronald A. Kapusta sold 2,935 shares of Johnson & Johnson stock in a transaction on Friday, July 22nd. The stock was sold at an average price of $125.01, for a total value of $366,904.35. Following the sale, the chief accounting officer now owns 28,660 shares in the company, valued at $3,582,786.60. The disclosure for this sale can be found here. Company insiders own 0.11% of the company’s stock.
Several large investors have recently added to or reduced their stakes in the company. Americafirst Capital Management LLC acquired a new stake in Johnson & Johnson during the second quarter worth approximately $101,000. Tuttle Tactical Management LLC acquired a new stake in Johnson & Johnson during the second quarter worth approximately $103,000. Lenox Wealth Management Inc. boosted its stake in Johnson & Johnson by 24.3% in the second quarter. Lenox Wealth Management Inc. now owns 972 shares of the company’s stock worth $118,000 after buying an additional 190 shares during the last quarter. Thomas J. Herzfeld Advisors Inc. boosted its stake in Johnson & Johnson by 221.2% in the second quarter. Thomas J. Herzfeld Advisors Inc. now owns 1,002 shares of the company’s stock worth $122,000 after buying an additional 690 shares during the last quarter. Finally, NCM Capital Management Group Inc. acquired a new stake in Johnson & Johnson during the second quarter worth approximately $127,000. Institutional investors own 65.32% of the company’s stock.
About Johnson & Johnson
Johnson & Johnson is a holding company, which is engaged in the research and development, manufacture and sale of a range of products in the healthcare field. The Company’s segments include Consumer, Pharmaceutical and Medical Devices. The Consumer segment includes a range of products used in the baby care, oral care, skin care, over-the-counter pharmaceutical, women’s health and wound care markets.
To view Vetr’s full report, visit Vetr’s official website.
Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.